MOA – DHA Replacement

DHA or docosahexaenoic acid is a major component of omega-3 fish oil and works differently than EPA, the other major omega-3 fatty acid in fish oil. Specifically, in sickle cell disease, multiple clinical trials have demonstrated high levels of DHA in the blood can help lower certain pro-inflammatory proteins and decrease oxidative stress within the bloodstream.

• Inflammation and oxidative stress are key components to triggering VOCs.
• Increased levels of DHA support cell membrane integrity, plasticity and fluidity
• Increased levels of DHA reduce hemoglobin mutation preventing oxidation
• Reduction in oxidation helps prevent RBC destruction (hemolysis)
• Overall inflammation is lowered by reduction in hemolysis.
• DHA critically serves to stop the inflammatory cascade (increases in WBC, platelets and adhesion molecules) leading to stickiness, clusters and blockages all causing VOCs.

When the oxidation and chronic inflammation is blocked, the remaining cascade of events(hypoxia/ lack of oxygen, sickling of cells, increased stickiness, clusters, blockages) leading to a vaso-inclusive crisis are greatly reduced.

ALTEMIA is the only eDHAtg replacement formulated specifically for sickle cell disease patients utilizing Natural Emulsion Technology™ to deliver reliable increased DHA levels safely and consistently to the bloodstream. There are no equivalents comparable to ALTEMIA’s purity, quality, safety and dosing convenience.